# Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake

> **NCT02883166** · PHASE1 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 14 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** abiraterone

## Key facts

- **NCT ID:** NCT02883166
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02883166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02883166, "Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02883166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*